scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-517-0730
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. View Scpharmaceuticals' Earnings History.
When is Scpharmaceuticals' next earnings date?
What price target have analysts set for SCPH?
4 equities research analysts have issued twelve-month price objectives for Scpharmaceuticals' shares. Their forecasts range from $5.00 to $14.00. On average, they anticipate Scpharmaceuticals' stock price to reach $10.3333 in the next twelve months. This suggests a possible upside of 189.4% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals.
What is the consensus analysts' recommendation for Scpharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scpharmaceuticals.
Has Scpharmaceuticals been receiving favorable news coverage?
Media stories about SCPH stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Scpharmaceuticals earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include Concert Pharmaceuticals (CNCE), Xenon Pharmaceuticals (XENE), Protagonist Therapeutics (PTGX), PhaseBio Pharmaceuticals (PHAS), Aduro BioTech (ADRO), Evelo Biosciences (EVLO), Mersana Therapeutics (MRSN), Aratana Therapeutics (PETX), Urovant Sciences (UROV), Calithera Biosciences (CALA), Verrica Pharmaceuticals (VRCA), Marinus Pharmaceuticals (MRNS), Kamada (KMDA), Lannett (LCI) and Syros Pharmaceuticals (SYRS).
What other stocks do shareholders of Scpharmaceuticals own?
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
- Dr. Pieter Muntendam, Consultant (Age 61)
- Ms. Rachael Nokes, Principal Accounting Officer
- Katherine Taudvin, Director of Corp. Devel. & Investor Relations
- Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Who are Scpharmaceuticals' major shareholders?
Scpharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.86%), Jacobs Levy Equity Management Inc. (0.13%), Parametric Portfolio Associates LLC (0.10%), SG Americas Securities LLC (0.09%) and Morgan Stanley (0.06%). Company insiders that own Scpharmaceuticals stock include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Scpharmaceuticals.
Which institutional investors are selling Scpharmaceuticals stock?
Which institutional investors are buying Scpharmaceuticals stock?
SCPH stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc. and SG Americas Securities LLC. Company insiders that have bought Scpharmaceuticals stock in the last two years include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Scpharmaceuticals.
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $3.57.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $66.33 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.
What is Scpharmaceuticals' official website?
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
